Nurix Therapeutics, Inc.
For the period ended May 31, 2025. Filed Jul 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
May 31, 2025 · Filed Jul 9, 2025
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2023 | 48,718,552 | $49 | $746,299 | $(655) | $(545,200) | $200,493 |
| Exercise of stock options | 75,362 | — | 355 | — | — | 355 |
| Vesting of restricted stock units | 171,030 | — | — | — | — | — |
| Vesting of early exercised stock options | — | — | 21 | — | — | 21 |
| Repurchase of unvested early exercised stock | (1,548) | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 173,558 | — | 1,269 | — | — | 1,269 |
| Stock-based compensation | — | — | 7,823 | — | — | 7,823 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 305 | — | 305 |
| Net loss | — | — | — | — | (41,518) | (41,518) |
| Balance as of February 29, 2024 | 49,136,954 | 49 | 755,767 | (350) | (586,718) | 168,748 |
| Issuance of common stock and pre-funded warrants in connection with equity financing, net of issuance costs of $12,518 | 11,916,667 | 12 | 188,720 | — | — | 188,732 |
| Issuance of common stock in “at the market” financing, net of issuance costs of $1,684 | 3,194,809 | 3 | 48,466 | — | — | 48,469 |
| Exercise of stock options | 24,108 | — | 216 | — | — | 216 |
| Vesting of restricted stock units | 83,997 | — | — | — | — | — |
| Vesting of early exercised stock options | — | — | 12 | — | — | 12 |
| Stock-based compensation | — | — | 8,847 | — | — | 8,847 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 215 | — | 215 |
| Net loss | — | — | — | — | (44,546) | (44,546) |
| Balance as of May 31, 2024 | 64,356,535 | $64 | $1,002,028 | $(135) | $(631,264) | $370,693 |
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulateddeficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2024 | 75,870,718 | $76 | $1,265,536 | $150 | $(738,769) | $526,993 |
| Exercise of stock options | 37,428 | — | 221 | — | — | 221 |
| Vesting of restricted stock units | 242,923 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 83,730 | — | 1,252 | — | — | 1,252 |
| Stock-based compensation | — | — | 8,726 | — | — | 8,726 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 76 | — | 76 |
| Net loss | — | — | — | — | (56,351) | (56,351) |
| Balance as of February 28, 2025 | 76,234,799 | 76 | 1,275,735 | 226 | (795,120) | 480,917 |
| Exercise of stock options | 1,233 | $— | 6 | — | — | 6 |
| Vesting of restricted stock units | 197,632 | $— | — | — | — | — |
| Stock-based compensation | — | $— | 10,390 | — | — | 10,390 |
| Unrealized loss on available-for-sale marketable securities | — | $— | — | (246) | — | (246) |
| Net loss | — | $— | — | — | (43,464) | (43,464) |
| Balance as of May 31, 2025 | 76,433,664 | $76 | $1,286,131 | $(20) | $(838,584) | $447,603 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.